A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of dupilumab in children 6 to <12 years of age with uncontrolled persistent asthma (2017–2019)
- Grant type:
- Sanofi-Aventis Australia Pty Ltd
- Researchers:
-
-
- Funded by:
- Sanofi-Aventis Australia Pty Ltd
